Columbia University

Raffaello Cortesini

Nicole Suciu-Foca

George Vlad

Luigi Scotto

Chih-Chao Chang

Zhuoru Liu

Seunghee Kim-Schulze

This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.

ILT3 polypeptides and uses thereof

This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.

ITL3 polypeptides and uses thereof

This invention also provides a method of generating antigen specific human suppressor CD8+CD28&#x2212; T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28&#x2212; T cells. Methods of tent for reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28&#x2212; T cells so produced are also provided, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.

Method of inducing anergic T helper cells

This invention provides a method of generating antigen specific allospecific human suppressor CD8&plus;CD28&minus; T cells. This invention also provides a method of generating xenospecific human suppressor CD8&plus;CD28&minus; T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8&plus;CD28&minus; T cells. Methods of treatment for reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8&plus;CD28&minus; T cells so produced are also provides, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.

Growing community of inventors

New York, NY, United States of America

Raffaello Cortesini